AI Article Synopsis
- - The AABB Clinical Transfusion Medicine Committee (CTMC) creates an annual overview of significant advancements in transfusion medicine, with a manuscript published since 2018.
- - Committee members review and discuss TM-related research papers from late 2019 to late 2020, selecting topics based on their relevance and originality before drafting synopses.
- - The final synopsis includes key subjects such as COVID-19's impacts on blood supply, convalescent plasma, adult and pediatric transfusion practices, and advances in cellular therapy, serving as a helpful educational resource.
Article Abstract
Background: The AABB Clinical Transfusion Medicine Committee (CTMC) compiles an annual synopsis of the published literature covering important developments in the field of transfusion medicine (TM), which has been made available as a manuscript published in Transfusion since 2018.
Methods: CTMC committee members reviewed original manuscripts including TM-related topics published electronically (ahead) or in print from December 2019 to December 2020. The selection of topics and manuscripts was discussed at committee meetings and chosen based on relevance and originality. Next, committee members worked in pairs to create a synopsis of each topic, which was then reviewed by two additional committee members. The first and senior authors of this manuscript assembled the final manuscript. Although this synopsis is extensive, it is not exhaustive, and some papers may have been excluded or missed.
Results: The following topics are included: COVID-19 effects on the blood supply and regulatory landscape, COVID convalescent plasma, adult transfusion practices, whole blood, molecular immunohematology, pediatric TM, cellular therapy, and apheresis medicine.
Conclusions: This synopsis provides easy access to relevant topics and may be useful as an educational tool.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630708 | PMC |
| http://dx.doi.org/10.1111/trf.16625 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
Nephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Lipopolysaccharide-Neutralizing Peptide Modulates P2X7 Receptor-Mediated Interleukin-1β Release.
ACS Pharmacol Transl Sci
January 2025
Pharmaceutical Institute, Pharmacology and Toxicology, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany.
Lipopolysaccharide (LPS)-neutralizing peptides are emerging as new potential therapeutic modalities to treat sepsis and skin infections. Purinergic ligand-gated ion channels (P2X receptors) play a critical role in various biological processes, including inflammation. Recent drug development efforts have significantly focused on the modulation of P2X receptors.
View Article and Find Full Text PDFUse of Oral and Intravenous Tranexamic Acid in Total Knee Arthroplasty and Total Hip Arthroplasty Procedures.
Cureus
December 2024
General Orthopedics, Midwest Bone and Joint Center, Macon, USA.
Introduction: Tranexamic acid (TXA) is an antifibrinolytic drug commonly used in total knee arthroplasty (TKA). Intravenous (IV) and topical TXA therapy have been extensively studied and shown to reduce blood loss, length of hospital stay, and blood transfusion rates following TKA. Despite the extensive literature regarding IV and topical TXA in orthopedics, there is a current dearth of studies analyzing oral usage.
View Article and Find Full Text PDFLiver injury in tuberculosis patients, associated with noncompliance with treatment, is further exacerbated by viral hepatitis, which not only directly harms the liver but also increases susceptibility to drug-induced liver injury. The aim of this study was to analyze the associated risk factors for viral hepatitis in tuberculosis patients. This systematic review and meta-analysis adhere to the PRISMA 2020 statement, and the protocol has been registered with PROSPERO (CRD42023477241).
View Article and Find Full Text PDFIntravenous administration of iron dextran as a potential inducer for hemochromatosis: Development of an iron overload animal model.
Narra J
December 2024
Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jatinangor, Indonesia.
Iron overload in transfusion-dependent thalassemia patients represents a significant public health challenge due to its high mortality rate and risks of severe complications. Therefore, developing safe and effective therapeutic modalities for managing iron overload is critical, as current animal models inadequately replicate human conditions. The aim of this study was to investigate the effects of intravenous iron dextran on hepatocyte morphology, liver iron concentration, and serum iron profile changes as a model for hemochromatosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!